Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

109.61 +0.41 (+0.38%)
Streaming Delayed Price Updated: 2:27 PM EST, Dec 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with... 
Via Benzinga
Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel
Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth... 
Via Benzinga
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Viking Therapeutics Is Having a Year to Remember: Time to Buy?
Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market. 
Via MarketBeat
Novo Nordisk Just Took a $530 Million Step Onto Moderna's Turf. Here's What It Means for Both Stocks
This strategic play will take time to pay off, but it could keep growth going. 
Via The Motley Fool
If You Invested $1000 In This Stock 10 Years Ago, You Would Have $5,700 Today
Via Benzinga
Evaluating Novo Nordisk: Insights From 8 Financial Analysts
Via Benzinga
What the Options Market Tells Us About Novo Nordisk
Via Benzinga
Novo Nordisk Inks $600M Genetic Medicines Pact With Canadian Firm To Target Cardiometabolic Indications
Wednesday, Canada-based NanoVation Therapeutics announced a multi-year partnership with Novo Nordisk A/S (NYSE:NVO) to advance the ... 
Via Benzinga
1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc)
Telemedicine once seemed like it was going to revolutionize healthcare. 
Via The Motley Fool
2 Unstoppable Healthcare Stocks to Buy Right Now for Less Than $200
No need to break the bank to get in on these excellent companies. 
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Stock Market Rally Revives; Apple iPhone 16, Nvidia, Oracle, Adobe In Focus: Weekly Review
The major indexes reclaimed key levels and many leaders flashed buy signals. 
Via Investor's Business Daily
Novo Nordisk Unusual Options Activity
Via Benzinga
3 No-Brainer Biotech Stocks to Buy With $200 Right Now
An investment in these players today could score a big win down the road. 
Via The Motley Fool
Why Roche Holdings Stock Withered on Wednesday
The company had a dispiriting update to offer about an investigational drug. 
Via The Motley Fool
Why Viking Therapeutics Stock Rocked the Market Today
The biotech continued to get attention from both pundits and investors, thanks largely to its investigational obesity drug. 
Via The Motley Fool
Novo Nordisk Jumps After New Weight-Loss Pill Tops Wegovy; Eli Lilly, Viking Shares Rise
The company is working on a drug that targets GLP-1 and amylin to improve weight loss. 
Via Investor's Business Daily
Ozempic Maker Novo Nordisk Touts Encouraging Data From New Obesity Pill Showing Double Weight Loss Compared To Wegovy
Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight loss in three months with adult participants. 
Via Benzinga
Is Hims & Hers Health the Next Teladoc?
Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. 
Via The Motley Fool
Exposures COVID-19
Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval
Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children... 
Via Benzinga
Exposures Product Safety
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Merck has seen its earnings invert over the past 12 months, driving earnings grow in its sector. What's going on with this pharma giant? 
Via MarketBeat
Billionaires Are Buying Viking Therapeutics Stock Left and Right. Should You Follow Their Lead?
The huge demand for effective new weight management drugs has billionaire investors feeling bullish about this stock. 
Via The Motley Fool
Goldman Sachs Shifts Stance On Novartis, Cites Lack Of Near-Term Catalysts
Goldman Sachs downgrades Novartis to Neutral, citing a lack of immediate innovative catalysts and limited stock growth potential. 
Via Benzinga
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation
Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. 
Via Benzinga
Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know.
Lilly just lowered the price of Zepbound. 
Via The Motley Fool
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Could this beaten-down stock turn things around in the near future? 
Via The Motley Fool
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
For those who appreciate growth without the sticker shock, NYSE:NVO is worth considering. 
Via Chartmill
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
66 67 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.